- Home
- NRIM vs RXST Comparison
NRIM vs RXST Comparison
Compare NRIM & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRIM | RXST |
|---|---|---|
| Founded | 1990 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 551.4M | 513.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NRIM | RXST |
|---|---|---|
| Price | $27.80 | $12.53 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $11.30 |
| AVG Volume (30 Days) | 130.7K | ★ 850.9K |
| Earning Date | 01-23-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | ★ 91.08 | N/A |
| EPS | ★ 2.80 | N/A |
| Revenue | ★ $201,544,000.00 | $142,085,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.55 | $4.18 |
| P/E Ratio | $9.86 | ★ N/A |
| Revenue Growth | ★ 42.34 | 10.75 |
| 52 Week Low | $16.18 | $6.32 |
| 52 Week High | $27.77 | $39.37 |
Technical Indicators
Market Signals| Indicator | NRIM | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 65.66 | 67.55 |
| Support Level | $24.17 | $11.84 |
| Resistance Level | $25.41 | $13.22 |
| Average True Range (ATR) | 0.97 | 0.65 |
| MACD | 0.59 | 0.05 |
| Stochastic Oscillator | 90.19 | 78.33 |
Price Performance
Historical ComparisonAbout NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.